Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $746.958M Est

Benzinga Newsdesk www.benzinga.com Negative 62.2%

Neg 62.2% Neu 0% Pos 0%

Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000 million to $730.000 million-$760.000 million vs $746.958 million estimate.